Experience in daily practice with ipilimumab for thetreatment of patients with metastatic melanoma: Anearly increase in lymphocyte and eosinophil countsis associated with improved survival

J. Delyon, C. Mateus, D. Lefeuvre, E. Lanoy, L. Zitvogel, N. Chaput, S. Roy, A. M.M. Eggermont, E. Routier, C. Robert

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

262 Citaten (Scopus)

Samenvatting

Background: Ipilimumab is a recently approved immunotherapy that has demonstrated an improvement in the overallsurvival (OS) of patients with metastatic melanoma. We report a single-institution experience in patients treated in acompassionate-use program.Patients and methods: In this prospective study, patients were treated between June 2010 and September 2011.Inclusion criteria were a diagnosis of unresectable stage III or IV melanoma, at least one previous line of chemotherapy,and survival 12 weeks after the first perfusion. Four courses of ipilimumab were administered at a dose of 3 mg/kgevery 3 weeks.

Originele taal-2Engels
Pagina's (van-tot)1697-1703
Aantal pagina's7
TijdschriftAnnals of Oncology
Volume24
Nummer van het tijdschrift6
DOI's
StatusGepubliceerd - jun. 2013
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Experience in daily practice with ipilimumab for thetreatment of patients with metastatic melanoma: Anearly increase in lymphocyte and eosinophil countsis associated with improved survival'. Samen vormen ze een unieke vingerafdruk.

Citeer dit